lapatinib has been researched along with mometasone furoate in 2 studies
| Studies (lapatinib) | Trials (lapatinib) | Recent Studies (post-2010) (lapatinib) | Studies (mometasone furoate) | Trials (mometasone furoate) | Recent Studies (post-2010) (mometasone furoate) |
|---|---|---|---|---|---|
| 1,919 | 305 | 1,442 | 913 | 355 | 439 |
| Protein | Taxonomy | lapatinib (IC50) | mometasone furoate (IC50) |
|---|---|---|---|
| Solute carrier organic anion transporter family member 1B3 | Homo sapiens (human) | 1.1481 | |
| Solute carrier organic anion transporter family member 1B1 | Homo sapiens (human) | 2.9512 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Egbert, M; Keserű, GM; Vajda, S; Whitty, A | 1 |
2 other study(ies) available for lapatinib and mometasone furoate
| Article | Year |
|---|---|
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Why Some Targets Benefit from beyond Rule of Five Drugs.
Topics: Binding Sites; Drug Discovery; Ligands; Molecular Weight; Protein Binding | 2019 |